Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 8.36 is 19% below its 5-year average of 10.30, near the low end of its 5-year range (0.40–52.78).
As of the fiscal period ended Tuesday, June 30, 2026. 13.58% below its 12-month average of 9.67.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 8.36.
QUICK RATIO (ACID-TEST)
8.36
QUICK RATIO (ACID-TEST) AVG TTM
9.67
QUICK RATIO (ACID-TEST) AVG 3Y
13.86
QUICK RATIO (ACID-TEST) AVG 5Y
10.30
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
-13.58%
CURRENT VS 3Y AVG
-39.71%
CURRENT VS 5Y AVG
-18.90%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.19
median of 741 covered companies
CURRENT VS SECTOR MEDIAN
+161.95%
vs the sector median at left
ProKidney Corp.
Market Cap
$536.32M
Quick Ratio (Acid-Test)
8.36
TTM Avg
9.67
3Y Avg
13.86
5Y Avg
10.30
Market Cap
$533.68M
Quick Ratio (Acid-Test)
25.13
TTM Avg
6.17
3Y Avg
7.34
5Y Avg
19.91
Market Cap
$539.58M
Quick Ratio (Acid-Test)
8.95
TTM Avg
10.43
3Y Avg
5.97
5Y Avg
5.34
Market Cap
$540.42M
Quick Ratio (Acid-Test)
1.87
TTM Avg
2.92
3Y Avg
5.55
5Y Avg
6.22
Market Cap
$524.44M
Quick Ratio (Acid-Test)
33.56
TTM Avg
31.41
3Y Avg
17.80
5Y Avg
16.41
Market Cap
$520.39M
Quick Ratio (Acid-Test)
9.66
TTM Avg
5.09
3Y Avg
5.58
5Y Avg
6.85
Market Cap
$549.33M
Quick Ratio (Acid-Test)
3.46
TTM Avg
4.63
3Y Avg
6.00
5Y Avg
6.13
Market Cap
$550.37M
Quick Ratio (Acid-Test)
1.68
TTM Avg
2.23
3Y Avg
2.63
5Y Avg
2.59
Market Cap
$519.25M
Quick Ratio (Acid-Test)
26.78
TTM Avg
15.83
3Y Avg
15.06
5Y Avg
15.09
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ProKidney Corp. (PROK) | $536.32M | 8.36 | 9.67 | 13.86 | 10.30 |
| Immix Biopharma, Inc. (IMMX)vs › | $533.68M | 25.13 | 6.17 | 7.34 | 19.91 |
| Delcath Systems, Inc. (DCTH)vs › | $539.58M | 8.95 | 10.43 | 5.97 | 5.34 |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $540.42M | 1.87 | 2.92 | 5.55 | 6.22 |
| Monopar Therapeutics Inc. (MNPR)vs › | $524.44M | 33.56 | 31.41 | 17.80 | 16.41 |
| Crescent Biopharma, Inc. (CBIO)vs › | $520.39M | 9.66 | 5.09 | 5.58 | 6.85 |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $549.33M | 3.46 | 4.63 | 6.00 | 6.13 |
| Nuvectis Pharma, Inc. (NVCT)vs › | $550.37M | 1.68 | 2.23 | 2.63 | 2.59 |
| Altimmune, Inc. (ALT)vs › | $519.25M | 26.78 | 15.83 | 15.06 | 15.09 |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $552.54M | 5.42 | 12.18 | 12.18 | 12.18 |
Quick Ratio
8.36
Excludes inventory
Current Ratio
8.36
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 8.36 |
| 2026-03-31 | 9.06 |
| 2025-12-31 | 9.13 |
| 2025-09-30 | 10.32 |
| 2025-06-30 | 11.48 |
| 2025-03-31 | 10.96 |
| 2024-12-31 | 10.93 |
| 2024-09-30 | 17.09 |
| 2024-06-30 | 21.87 |
| 2024-03-31 | 17.62 |
| 2023-12-31 | 14.94 |
| 2023-09-30 | 19.37 |
| 2023-06-30 | 19.04 |
| 2023-03-31 | 42.57 |
| 2022-12-31 | 46.42 |
| 2022-09-30 | 52.78 |
| 2022-06-30 | 0.74 |
| 2022-03-31 | 1.10 |
| 2021-12-31 | 2.21 |
| 2021-09-30 | 0.82 |
| 2021-06-30 | 0.40 |
| 2021-03-31 | 0.00 |
| 2020-12-31 | 1.02 |
